Government-Owned Inventions; Availability for Licensing, 16690-16692 [2013-06070]
Download as PDF
<![CDATA[
16690
Federal Register / Vol. 78, No. 52 / Monday, March 18, 2013 / Notices
approved service payback facility. The
Director reserves the right to make final
decisions regarding assignment of
scholarship recipients to fulfill their
service obligation.
Moreover, the Director, IHS, has the
authority to make the final
determination, designating a facility,
whether managed and operated by IHS,
or one of its Tribal or Urban Indian
partners, consistent with IHCIA, as
approved for scholar obligated service
payback.
pmangrum on DSK3VPTVN1PROD with NOTICES
3. Reporting
Scholarship Program Minimum
Academic Requirements
It is the policy of the IHS that a
scholarship awardee funded under the
Health Professions Scholarship Program
of the Indian Health Care Improvement
Act must maintain a 2.0 cumulative
GPA, remain in good academic standing
each semester/trimester/quarter,
maintain full-time student status
(Institutional definition of ‘minimum
hours’ constituting full-time enrollment
applies) or part-time student status
(Institutional definition of ‘minimum
and maximum’ hours constituting parttime enrollment applies) for the entire
academic year, as indicated on the
scholarship application submitted for
that academic year. The Health
Professions scholarship awardee may
not change his or her enrollment status
between terms of enrollment, during the
same academic year. In addition to these
requirements, a Health Professions
Scholarship awardee must be enrolled
in an approved/accredited school for a
Health Professions degree.
An awardee of a scholarship under
the IHS Health Professions Preparatory
and Health Professions Pre-Graduate
Scholarship authority must maintain a
minimum 2.0 cumulative GPA, remain
in good standing each semester/
trimester/quarter and be a full time
student (Institutional definition of
‘minimum hours’ constituting full-time
enrollment applies, typically 12 credit
hours per semester) or a part-time
student (Institutional definition of
‘minimum and maximum’ hours
constituting part-time enrollment
applies, typically 6–11 credit hours).
The Preparatory and Pre-graduate
awardee may not change from part-time
status to full-time status or vice versa in
the same academic year.
The following reports must be sent to
the IHSSP at the identified time frame.
Each scholarship awardee will have
access to an online Student Handbook
containing all required program forms
and instructions on when, how, and to
whom these must be submitted, by
VerDate Mar<14>2013
15:16 Mar 15, 2013
Jkt 229001
logging into the IHSSP Web site at
www.ihs.gov/scholarship. If a
scholarship awardee fails to submit
these forms and reports as required,
they will be ineligible for continuation
of scholarship support and scholarship
award payments will be discontinued.
A. Recipient’s Enrollment and Initial
Progress Report
Within thirty (30) days from the
beginning of each semester/trimester/
quarter, scholarship awardees must
submit a Recipient’s Enrollment and
Initial Progress Report (Form IHS–856–
8, page 69 of the Student Handbook).
B. Transcripts
Within thirty (30) days from the end
of each academic period, i.e., semester/
trimester/quarter, or summer session,
scholarship awardees must submit an
Official Transcript showing the results
of the classes taken during that period.
C. Notification of Academic Problem/
Change
If at any time during the semester/
trimester/quarter, scholarship awardees
are advised to reduce the number of
credit hours for which they are enrolled
below the minimum of the 12 (or the
number of hours considered by their
school as full-time) for a full-time
student or at least six hours for parttime students; or if they experience
academic problems, they must
immediately submit Form IHS–856–9,
on page 71 of the Student Handbook.
D. Change of Status
• Change of Academic Status
Scholarship awardees must
immediately notify their Scholarship
Program Analyst if they are placed on
academic probation, dismissed from
school, or voluntarily withdraw for any
reason (personal or medical).
• Change of Health Discipline
Scholarship awardees may not change
from the approved IHSSP health
discipline during the school year. If an
unapproved change is made,
scholarship payments will be
discontinued.
• Change in Graduation Date
Any time that a change occurs in a
scholarship awardee’s expected
graduation date, they must notify their
Scholarship Program Analyst
immediately in writing. Justification
must be attached from the school
advisor.
VII. Agency Contacts
1. Questions on the application
process may be directed to the
appropriate IHS Area Scholarship
Coordinator.
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
2. Questions on other programmatic
matters may be addressed to: Dr. Dawn
A. Kelly, Chief, Scholarship Program,
801 Thompson Avenue, TMP 450A,
Rockville, Maryland 20852, Telephone:
(301) 443–6197 (This is not a toll-free
number).
3. Questions on payment information
may be directed to: Mr. Craig Boswell,
Grants Scholarship Coordinator,
Division of Grants Management, Indian
Health Service, 801 Thompson Avenue,
TMP 360, Rockville, Maryland 20852,
Telephone: (301) 443–0243 (This is not
a toll-free number).
VIII. Other Information
The Public Health Service (PHS) is
committed to achieving the health
promotion and disease prevention
objectives of Health People 2020, a PHSled activity for setting priority areas.
This program announcement is related
to the priority area of Education and
Community-Based Programs. Potential
applicants may download a copy of
Healthy People 2020 from https://
www.healthypeople.gov.
Interested individuals are reminded
that the list of eligible health and allied
professions is effective for applicants for
the 2013–2014 academic year. These
priorities will remain in effect until
superseded. Applicants who apply for
health career categories not listed as
priorities during the current scholarship
cycle will not be considered for a
scholarship award.
Dated: March 11, 2013.
Yvette Roubideaux,
Director, Indian Health Service.
[FR Doc. 2013–06101 Filed 3–15–13; 8:45 am]
BILLING CODE 4165–16–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
SUMMARY:
E:\FR\FM\18MRN1.SGM
18MRN1
Federal Register / Vol. 78, No. 52 / Monday, March 18, 2013 / Notices
FOR FURTHER INFORMATION CONTACT:
pmangrum on DSK3VPTVN1PROD with NOTICES
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Ketone Bodies To Protect Tissues From
Damage by Ionizing Radiation
Description of Technology: The
invention relates to methods of using
ketogenic compounds to protect against
the adverse effects of radiation
exposure, including ionizing radiation
tissue damage. NIH inventors have
discovered that ketone esters can be
used to reduce tissue damage if
administered before or after exposure to
radiation. Specifically, the invention
relates to esters and oligomers of (R)-3hydroxybutyrate that are capable of
elevating blood levels of (R)-3hydroxybutyrate and acetoacetate to
sufficient levels to reduce cell death
caused by radiation-induced damage of
DNA and RNA. The development of
effective radioprotectant molecules such
as these is of great importance in
reducing tissue damage following
intentional or accidental radiation
exposure. This discovery can also
increase the therapeutic efficacy of
radiation therapies by protecting nontarget tissues from incidental radiation
damage.
Potential Commercial Applications:
• Effective therapeutic agent for
reducing tissue damage following
radiation exposure
• Protects populations subjected to
accidental, incidental, or military
exposure to radiation
• Protects non-target tissue during
radiation therapy
Competitive Advantages:
• Can be administered before or after
radiation damage
• Stable at room temperature,
allowing easy storage
Development Stage: In vitro data
available.
Inventor: Richard L. Veech (NIAAA).
Intellectual Property: HHS Reference
No. E–258–2012/0—US Application No.
61/722,630 filed 05 Nov 2012.
Licensing Contact: Charlene Sydnor,
Ph.D.; 301–435–4689;
sydnorc@mail.nih.gov.
Collaborative Research Opportunity:
The NIAAA is seeking statements of
capability or interest from parties
interested in collaborative research to
VerDate Mar<14>2013
15:16 Mar 15, 2013
Jkt 229001
further develop, evaluate or
commercialize Ketone Bodies to Protect
Tissues from Damage by Ionizing
Radiation. For collaboration
opportunities, please contact Peter B.
Silverman, Ph.D., J.D. at
psilverm@mail.nih.gov or 301–402–
6966.
mTOR Inhibition for the Prevention of
Epithelial Stem Cell Loss and Mucositis
Description of Technology: The
integrity of the epidermis and mucosal
epithelia is highly dependent on selfrenewing stem cells and, therefore, is
vulnerable to physical and chemical
damage from common cancer
treatments, such as radiation or
chemotherapy. Consequently, many
cancer patients undergoing these
treatments develop mucositis, a
debilitating condition involving painful
and deep mucosal ulcerations. Since
current prevention and treatment
options for mucositis are limited,
providing only minor relief and no
protection to stem cells, novel therapies
are needed.
The NIH inventors have recently
discovered that the mammalian target of
rapamycin (mTOR) mediates stem cells
exhaustion in the skin and leads to
progressive hair loss. More importantly,
they have shown that mTOR inhibition
reduces oxidative stress in the epithelial
stem cells and mTOR inhibitors can be
used to increase the re-populative
capacity of tissue resident stem cells to
maintain tissue homeostasis after injury
or stress. Therefore, this technology
could be used to prevent epithelial stem
cell loss and provide relief from
radiation-induced mucositis. Likewise,
it could be used to prevent mucositis
and hair loss in patients undergoing
chemotherapy and stem cell
transplantation. For optimal delivery
and effectiveness, rapamycin or other
mTOR inhibitor could be administered
in the form of a mouthwash or gel
product to patients prior to receiving
radiation (or other) treatments.
Potential Commercial Applications:
Prevention and treatment of epithelial
stem cell loss and mucositis.
Competitive Advantages:
• Reduces the oxidative stress in
epithelial stem cells and can increase
their repopulative capacity.
• Preserves the integrity of the oral
mucosa and protects from radiationinduced stem cell loss and mucositis.
Development Stage:
• Pre-clinical
• In vitro data available
• In vivo data available (animal)
Inventors: Silvio Gutkind (NIDCR),
Ramiro Iglesias-Bartolome (NIDCR),
Vyomesh Patel (NIDCR), Ana Cotrim
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
16691
(NIDCR), Alfredo Molinolo (NIDCR),
James Mitchell (NCI).
Publication: Iglesias-Bartolome R, et
al. mTOR inhibition prevents epithelial
stem cell senescence and protects from
radiation-induced mucositis. Cell Stem
Cell. 2012 Sep 7;11(3):401–14. [PMID
22958932].
Intellectual Property: HHS Reference
No. E–257–2012/0—U.S. Provisional
Application No. 61/696,681 filed 05 Sep
2012.
Related Technology: HHS Reference
No. E–300–2008—U.S. Patent
Application No. 13/376,984 filed 08 Dec
2011.
Licensing Contact: Whitney Hastings;
301–451–7337; hastingw@mail.nih.gov.
Combination Chemotherapeutics for the
Treatment of Chordoma
Description of Technology: Utilizing
high-throughput screening
methodology, NIH scientists have
identified two classes of clinicallyavailable drugs, proteasome inhibitors
and topoisomerase inhibitors, that
synergize to promote chordoma cell
death. Moreover, use of the two-part
chemotherapeutic regimen in animal
models effectively suppressed the
growth of chordoma cells and resulted
in significant tumor regression.
Currently, no chemotherapeutic agents
have been approved for the treatment of
chordoma. Using FDA approved drugs
in a combination therapeutic regimen
will help expedite the availability of a
therapeutic for chordoma.
Chordoma is a rare form of bone
cancer that arises within the skull,
sacrum or bony spine. Surgical resection
and radiation therapy are the current
standards-of-care; however, posttreatment complications remain
significant and neither modality is
effective for the control of metastatic
tumors.
Potential Commercial Applications:
• Chemotherapeutic regimen for the
treatment of inoperable chordomas.
• Therapy for the treatment of
recurrent or metastatic chordomas.
• Therapeutic kit combining an FDAapproved proteasome inhibitor with a
topoisomerase inhibitor.
Competitive Advantages:
• Therapy utilizes FDA-approved
drugs with known pharmacokinetics
and safety profiles.
• Reduced drug dosing from
combination therapy may result in
fewer patient side effects.
• Combination therapy inhibits
multiple molecular targets, enhancing
disease response.
Development Stage:
• Pre-clinical
• In vitro data available
E:\FR\FM\18MRN1.SGM
18MRN1
16692
Federal Register / Vol. 78, No. 52 / Monday, March 18, 2013 / Notices
• In vivo data available (animal)
Inventors: Menghang Xia, Ruili
Huang, Christopher P. Austin (all of
NCATS).
Intellectual Property: HHS Reference
No. E–156–2012/0—US Application No.
61/692,560 filed 23 Aug 2012.
Licensing Contact: Sabarni Chatterjee,
Ph.D., MBA; 301–435–5587;
chatterjeesa@mail.nih.gov.
Collaborative Research Opportunity:
The National Center for Advancing
Translational Sciences, Division of PreClinical Innovation, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize Combination
Chemotherapeutics for the Treatment of
Chordoma. For collaboration
opportunities, please contact Lili M.
Portilla, MPA at lilip@nih.gov.
Dated: March 8, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2013–06070 Filed 3–15–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up Option
Exclusive License: The Development
of Liposomal Therapeutic Agents for
the Treatment of Human Epithelial
Cancers and Liposarcomas
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant to ZoneOne
Pharma, Inc., of an exclusive evaluation
option license to practice the inventions
embodied in the following US Patent
(and all foreign counterparts): Serial No.
6,890,917 entitled, ‘‘Geldanamycin
Derivative and Method of Treating
Cancer Using Same’’ [HHS Ref. E–050–
2000/0–US–15]. The patent rights in
this invention have been assigned to the
Government of the United States of
America.
The prospective exclusive evaluation
option license territory may be
worldwide, and the field of use may be
limited to:
pmangrum on DSK3VPTVN1PROD with NOTICES
SUMMARY:
The pharmaceutical use in humans of 17dimethylaminoethylamino-17-
VerDate Mar<14>2013
15:16 Mar 15, 2013
Jkt 229001
demethoxygeldanamycin (‘‘17–DMAG’’) as a
liposome-encapsulated drug, alone or in
combination with other agents, for the
treatment of the following types of cancer:
ovary, pancreas, metastatic skin, head and
neck, colon, kidney, non-small cell lung, or
liposarcoma.
Dated: March 8, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
& Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2013–06069 Filed 3–15–13; 8:45 am]
BILLING CODE 4140–01–P
Upon the expiration or termination of
the exclusive evaluation option license,
ZoneOne Pharma, Inc., will have the
exclusive right to execute an exclusive
commercialization license which will
supersede and replace the exclusive
evaluation option license with no
greater field of use and territory than
granted in the exclusive evaluation
option license.
Only written comments or
applications for a license (or both)
which are received by the NIH Office of
Technology Transfer on or before April
2, 2013 will be considered.
DATES:
Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive evaluation
option license should be directed to:
Patrick McCue, Ph.D., Licensing and
Patenting Manager, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
Telephone: (301) 435–5560; Facsimile:
(301) 402–0220; Email:
mccuepat@mail.nih.gov.
ADDRESSES:
This
invention concerns 17–DMAG, the first
water-soluble analog of 17–AAG, a less
toxic and more stable analog of the
antitumor antibiotic geldanamycin.
The prospective exclusive evaluation
license is being considered under the
small business initiative launched on 1
October 2011, and will comply with the
terms and conditions of 35 U.S.C. 209
and 37 CFR 404.7. The prospective
exclusive evaluation license, and a
subsequent exclusive commercialization
license, may be granted unless the NIH
receives written evidence and argument
that establishes that the grant of the
license would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7 within fifteen (15) days from
the date of this published notice.
Complete applications for a license in
the field of use filed in response to this
notice will be treated as objections to
the grant of the contemplated exclusive
evaluation option license. Comments
and objections submitted to this notice
will not be made available for public
inspection and, to the extent permitted
by law, will not be released under the
Freedom of Information Act, 5 U.S.C.
552.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
DEPARTMENT OF HOMELAND
SECURITY
[Docket No. DHS–2012–0059]
Chemical Facility Anti-Terrorism
Standards (CFATS)
National Protection and
Programs Directorate, DHS.
ACTION: 30-day notice and request for
comments; Extension of Information
Collection Request: 1670–0014.
AGENCY:
The Department of Homeland
Security (DHS), National Protection and
Programs Directorate (NPPD), Office of
Infrastructure Protection (IP),
Infrastructure Security Compliance
Division (ISCD) will submit the
following Information Collection
Request (ICR) to the Office of
Management and Budget (OMB) for
review and clearance in accordance
with the Paperwork Reduction Act of
1995 (Pub. L. 104–13, 44 U.S.C. Chapter
35). The Department previously
published this ICR in the Federal
Register on December 17, 2012, for a 60day public comment period.1 In this
notice, NPPD is responding to one
comment 2 and is soliciting public
comments concerning the extension of
Information Collection Request,
Chemical Facility Anti-Terrorism
Standards (CFATS) for an additional 30
days.
DATES: Comments are encouraged and
will be accepted until April 17, 2013.
This process is conducted in accordance
with 5 CFR 1320.10.
ADDRESSES: Interested persons are
invited to submit written comments on
the proposed information collection to
the Office of Information and Regulatory
Affairs, OMB. Comments should be
addressed to OMB Desk Officer,
Department of Homeland Security,
National Protection and Programs
Directorate. Comments must be
SUMMARY:
1 See 77 FR 74677. The 60-day Federal Register
notice for Information Collection 1670–0014, which
solicited comments for 60 days, may be found at
https://federalregister.gov/a/2012-30314.
2 The comment was submitted under docket #
DHS–2012–0059 and provided comment not only
on this information collection request (i.e., 1670–
0014), but also on ICR 1670–0007 and ICR 1670–
0015. The comment may be viewed at https://
www.regulations.gov/#!documentDetail;D=DHS2012-0059-0002.
E:\FR\FM\18MRN1.SGM
18MRN1
]]>Agencies
[Federal Register Volume 78, Number 52 (Monday, March 18, 2013)]
[Notices]
[Pages 16690-16692]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-06070]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
[[Page 16691]]
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
Ketone Bodies To Protect Tissues From Damage by Ionizing Radiation
Description of Technology: The invention relates to methods of
using ketogenic compounds to protect against the adverse effects of
radiation exposure, including ionizing radiation tissue damage. NIH
inventors have discovered that ketone esters can be used to reduce
tissue damage if administered before or after exposure to radiation.
Specifically, the invention relates to esters and oligomers of (R)-3-
hydroxybutyrate that are capable of elevating blood levels of (R)-3-
hydroxybutyrate and acetoacetate to sufficient levels to reduce cell
death caused by radiation-induced damage of DNA and RNA. The
development of effective radioprotectant molecules such as these is of
great importance in reducing tissue damage following intentional or
accidental radiation exposure. This discovery can also increase the
therapeutic efficacy of radiation therapies by protecting non-target
tissues from incidental radiation damage.
Potential Commercial Applications:
Effective therapeutic agent for reducing tissue damage
following radiation exposure
Protects populations subjected to accidental, incidental,
or military exposure to radiation
Protects non-target tissue during radiation therapy
Competitive Advantages:
Can be administered before or after radiation damage
Stable at room temperature, allowing easy storage
Development Stage: In vitro data available.
Inventor: Richard L. Veech (NIAAA).
Intellectual Property: HHS Reference No. E-258-2012/0--US
Application No. 61/722,630 filed 05 Nov 2012.
Licensing Contact: Charlene Sydnor, Ph.D.; 301-435-4689;
sydnorc@mail.nih.gov.
Collaborative Research Opportunity: The NIAAA is seeking statements
of capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize Ketone Bodies to
Protect Tissues from Damage by Ionizing Radiation. For collaboration
opportunities, please contact Peter B. Silverman, Ph.D., J.D. at
psilverm@mail.nih.gov or 301-402-6966.
mTOR Inhibition for the Prevention of Epithelial Stem Cell Loss and
Mucositis
Description of Technology: The integrity of the epidermis and
mucosal epithelia is highly dependent on self-renewing stem cells and,
therefore, is vulnerable to physical and chemical damage from common
cancer treatments, such as radiation or chemotherapy. Consequently,
many cancer patients undergoing these treatments develop mucositis, a
debilitating condition involving painful and deep mucosal ulcerations.
Since current prevention and treatment options for mucositis are
limited, providing only minor relief and no protection to stem cells,
novel therapies are needed.
The NIH inventors have recently discovered that the mammalian
target of rapamycin (mTOR) mediates stem cells exhaustion in the skin
and leads to progressive hair loss. More importantly, they have shown
that mTOR inhibition reduces oxidative stress in the epithelial stem
cells and mTOR inhibitors can be used to increase the re-populative
capacity of tissue resident stem cells to maintain tissue homeostasis
after injury or stress. Therefore, this technology could be used to
prevent epithelial stem cell loss and provide relief from radiation-
induced mucositis. Likewise, it could be used to prevent mucositis and
hair loss in patients undergoing chemotherapy and stem cell
transplantation. For optimal delivery and effectiveness, rapamycin or
other mTOR inhibitor could be administered in the form of a mouthwash
or gel product to patients prior to receiving radiation (or other)
treatments.
Potential Commercial Applications: Prevention and treatment of
epithelial stem cell loss and mucositis.
Competitive Advantages:
Reduces the oxidative stress in epithelial stem cells and
can increase their repopulative capacity.
Preserves the integrity of the oral mucosa and protects
from radiation-induced stem cell loss and mucositis.
Development Stage:
Pre-clinical
In vitro data available
In vivo data available (animal)
Inventors: Silvio Gutkind (NIDCR), Ramiro Iglesias-Bartolome
(NIDCR), Vyomesh Patel (NIDCR), Ana Cotrim (NIDCR), Alfredo Molinolo
(NIDCR), James Mitchell (NCI).
Publication: Iglesias-Bartolome R, et al. mTOR inhibition prevents
epithelial stem cell senescence and protects from radiation-induced
mucositis. Cell Stem Cell. 2012 Sep 7;11(3):401-14. [PMID 22958932].
Intellectual Property: HHS Reference No. E-257-2012/0--U.S.
Provisional Application No. 61/696,681 filed 05 Sep 2012.
Related Technology: HHS Reference No. E-300-2008--U.S. Patent
Application No. 13/376,984 filed 08 Dec 2011.
Licensing Contact: Whitney Hastings; 301-451-7337;
hastingw@mail.nih.gov.
Combination Chemotherapeutics for the Treatment of Chordoma
Description of Technology: Utilizing high-throughput screening
methodology, NIH scientists have identified two classes of clinically-
available drugs, proteasome inhibitors and topoisomerase inhibitors,
that synergize to promote chordoma cell death. Moreover, use of the
two-part chemotherapeutic regimen in animal models effectively
suppressed the growth of chordoma cells and resulted in significant
tumor regression. Currently, no chemotherapeutic agents have been
approved for the treatment of chordoma. Using FDA approved drugs in a
combination therapeutic regimen will help expedite the availability of
a therapeutic for chordoma.
Chordoma is a rare form of bone cancer that arises within the
skull, sacrum or bony spine. Surgical resection and radiation therapy
are the current standards-of-care; however, post-treatment
complications remain significant and neither modality is effective for
the control of metastatic tumors.
Potential Commercial Applications:
Chemotherapeutic regimen for the treatment of inoperable
chordomas.
Therapy for the treatment of recurrent or metastatic
chordomas.
Therapeutic kit combining an FDA-approved proteasome
inhibitor with a topoisomerase inhibitor.
Competitive Advantages:
Therapy utilizes FDA-approved drugs with known
pharmacokinetics and safety profiles.
Reduced drug dosing from combination therapy may result in
fewer patient side effects.
Combination therapy inhibits multiple molecular targets,
enhancing disease response.
Development Stage:
Pre-clinical
In vitro data available
[[Page 16692]]
In vivo data available (animal)
Inventors: Menghang Xia, Ruili Huang, Christopher P. Austin (all of
NCATS).
Intellectual Property: HHS Reference No. E-156-2012/0--US
Application No. 61/692,560 filed 23 Aug 2012.
Licensing Contact: Sabarni Chatterjee, Ph.D., MBA; 301-435-5587;
chatterjeesa@mail.nih.gov.
Collaborative Research Opportunity: The National Center for
Advancing Translational Sciences, Division of Pre-Clinical Innovation,
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate or commercialize
Combination Chemotherapeutics for the Treatment of Chordoma. For
collaboration opportunities, please contact Lili M. Portilla, MPA at
lilip@nih.gov.
Dated: March 8, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-06070 Filed 3-15-13; 8:45 am]
BILLING CODE 4140-01-P
